Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
85.64
-4.36 (-4.84%)
At close: Dec 1, 2025, 4:00 PM EST
86.43
+0.79 (0.92%)
After-hours: Dec 1, 2025, 6:57 PM EST
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Protagonist Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $86.44, which forecasts a 0.93% increase in the stock price over the next year. The lowest target is $73 and the highest is $102.
Price Target: $86.44 (+0.93%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $96 → $98 | Strong Buy | Maintains | $96 → $98 | +14.43% | Nov 10, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $68 → $81 | Buy | Maintains | $68 → $81 | -5.42% | Nov 7, 2025 |
| Barclays | Barclays | Buy Maintains $72 → $88 | Buy | Maintains | $72 → $88 | +2.76% | Nov 7, 2025 |
| Citizens | Citizens | Buy Maintains $69 → $102 | Buy | Maintains | $69 → $102 | +19.10% | Nov 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $76 → $88 | Strong Buy | Maintains | $76 → $88 | +2.76% | Oct 28, 2025 |
Financial Forecast
Revenue This Year
66.12M
from 434.43M
Decreased by -84.78%
Revenue Next Year
262.15M
from 66.12M
Increased by 296.47%
EPS This Year
-1.97
from 4.23
EPS Next Year
-0.65
from -1.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 271.9M | 551.3M | ||||
| Avg | 66.1M | 262.2M | ||||
| Low | 37.8M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -37.4% | 733.7% | ||||
| Avg | -84.8% | 296.5% | ||||
| Low | -91.3% | -70.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.32 | 5.29 | ||||
| Avg | -1.97 | -0.65 | ||||
| Low | -2.28 | -2.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.